Overview

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors

Status:
Recruiting

Trial end date:
2027-04-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of CFT1946 as well as to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CFT1946 as monotherapy (Arm A) and in combination with trametinib (CFT1946 + trametinib; Arm B).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

C4 Therapeutics, Inc.

Treatments:

Trametinib